pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 15·1 min read
save

Coronary artery disease deaths in US have halved since 1990, but most recent deaths remain preventable

Jul 15, 2026·read at STAT ↗Positive

A new analysis published in JAMA Cardiology shows that deaths from ischemic heart disease in the United States dropped by more than half between 1990 and 2023. The decline is attributed to improved control of a range of risk factors, especially reductions in smoking and particulate air pollution.

Despite the progress, the study estimates that 88.8% of the 473,000 coronary artery disease deaths in 2023 were still associated with modifiable risk factors. The authors highlight that nearly nine out of ten recent deaths could have been avoided with better risk‑factor management.

The report also notes rising concerns, such as increases in body‑mass index and blood‑glucose levels since 1990, which reflect growing prevalence of obesity and diabetes. The authors argue that further reductions in coronary deaths will require renewed focus on these emerging risk drivers.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Deaths from coronary artery disease have fallen, but more progress is within reach”

read at STAT ↗
1,399 words · retrieved Jul 15
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING3RISINGUniversity of Washington
drugs
Obesity3
topics
Cardiology25Hematology6Endocrinology & Metabolism5Nephrology5Obesity4Type 2 Diabetes4Hypertension3Hyperlipidemia2Breast CancerDrug ShortageOncology

related stories

  • Jul 1Statins and blood pressure drugs changing health risks of obesity, study suggestsSTAT
  • 15h ago‘Tactical athletes’ get new guidance for cardiovascular fitnessSTAT
  • Jul 18Opinion: STAT readers on the value of primary care, obesity as a disease, and moreSTAT
  • Jul 10Opinion: The primary care crisis paradoxSTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive